INV vs XOMA vs RPRX vs BCYC vs RCUS

For growth investors, Bicycle Therapeutics plc (BCYC) is the stronger pick with 105.

8% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Royalty Pharma plc (RPRX) offers the better valuation at 28. 2x trailing P/E (9. 9x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Royalty Pharma plc (RPRX) is the cheapest at 28.

2x versus XOMA Royalty Corp. at 28. 7x. On forward P/E, Royalty Pharma plc is actually cheaper at 9. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Royalty Pharma plc wins at 1. 40x versus XOMA Royalty Corp. 's 3. 99x — a reasonable growth-adjusted valuation.

Over the past 5 years, XOMA Royalty Corp.

(XOMA) delivered a total return of +36. 8%, compared to -84. 4% for Bicycle Therapeutics plc (BCYC). Over 10 years, the gap is even starker: XOMA returned +190. 9% versus BCYC's -59. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.

43β versus Innventure, Inc. 's 2. 81β — meaning INV is approximately 554% more volatile than RPRX relative to the S&P 500. On balance sheet safety, Bicycle Therapeutics plc (BCYC) carries a lower debt/equity ratio of 3% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bicycle Therapeutics plc (BCYC) is pulling ahead at 105.

8% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -143. 1% for Innventure, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus -64. 1% for Innventure, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65. 6% versus -63. 2% for INV. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Royalty Pharma plc (RPRX) is the more undervalued stock at a PEG of 1. 40x versus XOMA Royalty Corp. 's 3. 99x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Royalty Pharma plc (RPRX) trades at 9. 9x forward P/E versus 53. 3x for XOMA Royalty Corp. — 43. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BCYC: 121. 8% to $10. 67.

In this comparison, RPRX (1.

3% yield), XOMA (0. 7% yield), INV (0. 2% yield) pay a dividend. BCYC, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

43), 1. 3% yield). Innventure, Inc. (INV) carries a higher beta of 2. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RPRX: +24. 2%, INV: -30. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INV (Financial Services) and XOMA (Healthcare) and RPRX (Healthcare) and BCYC (Healthcare) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INV is a small-cap quality compounder stock; XOMA is a small-cap high-growth stock; RPRX is a mid-cap quality compounder stock; BCYC is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. XOMA, RPRX pay a dividend while INV, BCYC, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.